A PHASE 1B/2, OPEN-LABEL DOSE ESCALATION WITH EXPANSION STUDY OF GB5121 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, WITH A PHASE 2 OPEN-LABEL SINGLE DOSE LEVEL STUDY OF GB5121 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Registry ID

GB5121-2101

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

GB005, INC.

Start date

2023-01-13

Completion date

2023-08-21

Last update

2022-01-11

Conditions

• CENTRAL NERVOUS SYSTEM LYMPHOMA

Related clinical trials

• A PHASE 2 STUDY OF IBRUTINIB COMBINATION THERAPY IN TRANSPLANT INELIGIBLE INDIVIDUALS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

View on source registry